2.2700
-0.0500
(-2.16%)
At close: April 8 at 4:00:02 PM EDT
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 6 | 6 | 7 | 6 |
| Avg. Estimate | -0.22 | -0.23 | -0.89 | -0.81 |
| Low Estimate | -0.27 | -0.28 | -1.02 | -1.02 |
| High Estimate | -0.15 | -0.18 | -0.65 | -0.52 |
| Year Ago EPS | -0.22 | -0.22 | -0.94 | -0.89 |
Revenue Estimate
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 7 | 7 | 9 | 8 |
| Avg. Estimate | 1.07M | 1.3M | 11.39M | 40.39M |
| Low Estimate | -- | -- | 4.5M | 5.2M |
| High Estimate | 1.6M | 2.3M | 33.05M | 152.34M |
| Year Ago Sales | 898k | 1.27M | 4.53M | 11.39M |
| Sales Growth (year/est) | 19.31% | 2.36% | 151.31% | 254.46% |
Earnings History
| Currency in USD | 3/31/2024 | 6/30/2024 | 9/30/2024 | 12/31/2024 |
|---|---|---|---|---|
| EPS Est. | -0.2 | -0.18 | -0.19 | -0.22 |
| EPS Actual | -0.22 | -0.22 | -0.24 | -0.25 |
| Difference | -0.02 | -0.04 | -0.04 | -0.03 |
| Surprise % | -11.86% | -20.00% | -23.08% | -11.73% |
EPS Trend
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Current Estimate | -0.22 | -0.23 | -0.89 | -0.81 |
| 7 Days Ago | -0.18 | -0.17 | -0.75 | -0.65 |
| 30 Days Ago | -0.18 | -0.17 | -0.75 | -0.65 |
| 60 Days Ago | -0.18 | -0.17 | -0.75 | -0.65 |
| 90 Days Ago | -0.16 | -0.14 | -0.74 | -0.6 |
EPS Revisions
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Up Last 7 Days | 1 | -- | 2 | 2 |
| Up Last 30 Days | 1 | -- | 2 | 2 |
| Down Last 7 Days | 2 | 2 | 4 | 2 |
| Down Last 30 Days | 1 | 1 | 4 | 1 |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| ABSI | -1.51% | -6.82% | 5.78% | 8.17% |
| S&P 500 | 6.55% | 6.50% | 9.70% | 14.29% |
Upgrades & Downgrades
| Reiterates | Guggenheim: Buy to Buy | 3/20/2025 |
| Reiterates | Needham: Buy to Buy | 3/19/2025 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 3/19/2025 |
| Initiated | Needham: Buy | 1/22/2025 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 1/17/2025 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 1/10/2025 |
Related Tickers
RXRX Recursion Pharmaceuticals, Inc.
3.9700
-5.48%
PRME Prime Medicine, Inc.
1.1500
-11.54%
BEAM Beam Therapeutics Inc.
14.54
-4.97%
ABCL AbCellera Biologics Inc.
1.9300
-5.85%
SANA Sana Biotechnology, Inc.
1.3400
-12.42%
NTLA Intellia Therapeutics, Inc.
6.28
-3.98%
RLAY Relay Therapeutics, Inc.
2.0000
-2.44%
DNA Ginkgo Bioworks Holdings, Inc.
5.76
-10.14%
FATE Fate Therapeutics, Inc.
0.9058
-0.40%
IOVA Iovance Biotherapeutics, Inc.
2.8500
-5.94%